Myriad Genetics (NASDAQ:MYGN) executives highlighted fourth quarter and full-year 2025 results alongside a slate of planned ...
SiBone (NASDAQ:SIBN) executives highlighted record revenue, increased physician adoption, and a shift to profitability metrics in the company’s fourth-quarter 2025 earnings call, while outlining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results